Q1 2023 13F Holders as of 31 Mar 2023
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
8,165,808
-
Total 13F shares
-
102,669,151
-
Share change
-
+5,200,550
-
Total reported value
-
$297,703,409
-
Put/Call ratio
-
0.55%
-
Price per share
-
$2.90
-
Number of holders
-
122
-
Value change
-
+$14,378,402
-
Number of buys
-
58
-
Number of sells
-
63
Institutional Holders of Atara Biotherapeutics, Inc. - Common Stock (ATRA) as of Q1 2023
As of 31 Mar 2023,
Atara Biotherapeutics, Inc. - Common Stock (ATRA) was held by
122 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
102,669,151 shares.
The largest 10 holders included
BlackRock Inc., BAUPOST GROUP LLC/MA, WASATCH ADVISORS LP, STATE STREET CORP, JPMORGAN CHASE & CO, VANGUARD GROUP INC, GOLDMAN SACHS GROUP INC, MAVERICK CAPITAL LTD, Redmile Group, LLC, and D. E. Shaw & Co., Inc..
This page lists
123
institutional shareholders reporting positions in this security
for the Q1 2023 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.